Business
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplantREDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results from a prior Phase 2 clinical study evaluating burixafor (GPC-100/TG-0054), a highl
About this update from Exicure, Inc.
[{"type":"image","alt":"Exicure, Inc.","displaySize":"","headline":null,"caption":"Exicure, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/da589576ac3c0eee6f177a324fea5872"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ORrzxbIO3.kd.Z_9IrCfrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/da589576ac3c0eee6f177a324fea5872","width":300,"height":74}},"lazy":false},{"type":"text","content":"Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant","length":199,"tagName":"p"},{"type":"text","content":"REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results from a prior Phase 2 clinical study evaluating burixafor (GPC-100/TG-0054), a highly selective CXCR4 inhibitor, in the journal Annals of Hematology.","length":371,"tagName":"p"},{"type":"text","content":"The manuscript, titled “Burixafor, a CXCR4 Inhibitor with a Differentiated Kinetics Profile: Results of a Phase 2 Study for Rapid Cell Mobilization in Multiple Myeloma and Lymphoma Patients Undergoing Transplant,” reports results from a 12-participant, multi-center, open-label Phase 2 study (NCT02104427) evaluating burixafor in combination with granulocyte colony-stimulating factor (G-CSF) in patients with multiple myeloma (MM), non-Hodgkin’s lymphoma (NHL), and Hodgkin disease (HD) undergoing autologous stem cell transplantation (ASCT).","length":543,"tagName":"p"},{"type":"text","content":"In the study, 11 of 12 participants (92%) met the primary endpoint of collecting ≥5.0 × 10⁶ CD34+ cells/kg within two leukapheresis sessions, with six participants achieving the target in a single session. Median time to neutrophil and platelet engraftment was 12 and 22 days, respectively. Burixafor was generally well tolerated, with only two treatment-related adverse events reported, both low grade.","length":403,"tagName":"p"},{"type":"text","content":"Notably, peak mobilization of CD34+ cells occurred within one hour of burixafor administration, substantially fast...